8-K 1 a20170222form8-k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
February 23, 2017
Date of Report (Date of earliest event reported)
Flex Pharma, Inc.
(Exact name of registrant as specified in its charter)

Delaware |  | 001-36812 |  | 46-5087339
(State or other jurisdiction |  | (Commission File Number) |  | (IRS Employer Identification No.)
of incorporation) |  |  |  |

800 Boylston Street, 24 th Floor Boston, MA |  | 02199
(Address of principal executive offices) |  | (Zip Code)

Registrant’s telephone number, including area code: (617) 874-1821
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.
On February 23, 2017, Flex Pharma, Inc. (the "Company") will present a poster entitled "Flex-201: A Multicenter, Randomized, Blinded Study to Evaluate the Efficacy and Tolerability of FLX-787 in MS" at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2017 Forum. The poster is furnished herewith as Exhibit 99.1.
The information contained in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits

Exhibit No. |  | Description
99.1 |  |  | Flex Pharma, Inc. poster.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Flex Pharma, Inc.
Dated: February 23, 2017 |
| By: | /s/ Robert Hadfield
|  | Robert Hadfield
|  | General Counsel and Secretary

INDEX TO EXHIBITS

Exhibit No. |  | Description
99.1 |  |  | Flex Pharma, Inc. poster.